KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals has reported Total Current Liabilities over the past 9 years, most recently at $881.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 21.96% year-over-year to $881.6 million; the TTM value through Dec 2025 reached $881.6 million, down 21.96%, while the annual FY2025 figure was $881.6 million, 21.96% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $881.6 million at Amneal Pharmaceuticals, up from $862.1 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $1.1 billion in Q4 2024 and troughed at $602.0 million in Q1 2022.
  • A 5-year average of $850.4 million and a median of $826.2 million in 2022 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: crashed 34.02% in 2021 and later skyrocketed 47.59% in 2022.
  • Year by year, Total Current Liabilities stood at $677.2 million in 2021, then grew by 11.16% to $752.8 million in 2022, then increased by 12.46% to $846.6 million in 2023, then soared by 33.45% to $1.1 billion in 2024, then dropped by 21.96% to $881.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for AMRX at $881.6 million in Q4 2025, $862.1 million in Q3 2025, and $1.1 billion in Q2 2025.